Using Health-related Quality of Life (HRQL) in Routine Clinical Care
An Assessment of the Effects of the Use of Measures of Health-related Quality of Life in Routine Clinical Care:an Application to Lung Transplantation.
The objective of this study is to assess the effects of using HRQL measures in the clinical care of pre- and post-lung transplant patients.
The hypotheses are that the inclusion of HRQL measures, the Health Utilities Index System Mark 2(HUI2) and Mark 3 (HUI3), in routine clinical care of pre- and post-lung transplant patients, will: 1) improve patient-clinician communication;2) affect patient management; 3) improve patients' HRQL.
Přehled studie
Postavení
Intervence / Léčba
Detailní popis
Recently there has been increasing interest in the use of health-related quality of life (HRQL) measures in routine clinical practice. Traditionally, patient care has been based on laboratory results, medical history, and signs and symptoms diagnosed by clinicians. The inclusion of HRQL measures in routine practice may provide important and often otherwise missing information, revealing the impact of the disease or its treatment on the patient's physical, emotional and social well-being, and may assist in patient management. HRQL assessments may assist in changing the medical paradigm from a disease-centered approach to a patient-centered one.
Several studies in mental health and oncology discuss the application of HRQL measures in clinical practice. Taenzer et al (2000) and Detmar et al. (2002) provide evidence that using HRQL measures improves patient-clinician communication. Velikova et al (2004) detected impacts on communication and the emotional well-being of patients.
Using a framework based on these previous studies and the methods for the health technology assessment of diagnostic technologies (Guyatt et al. 1986), we will assess the effects of including HRQL assessments in the routine clinical care of patients undergoing solid organ transplantation (lung).
We expect that the routine use of HRQL measures in clinical practice will affect patient-clinician communication, patient management, and patient outcome.
Lung transplantation trades a fatal disease (end-stage pulmonary disease) for a chance at prolonged survival and improved quality of life, albeit with immunosuppression. In this context, generic preference-based measures such as HUI2 and HUI3 are preferred to specific measures, because they measure a broader range of health dimensions, including pain, ambulation and emotional issues that are expected to be relevant. Preference-based measures provide scores on the conventional 0.00 (dead) to 1.00 (perfect health) scale that allows for the integration of morbidity and mortality effects and calculation of quality adjusted life years (QALYs) and health-adjusted life expectancy (HALE).
Typ studie
Zápis (Aktuální)
Kontakty a umístění
Studijní místa
-
-
Alberta
-
Edmonton, Alberta, Kanada
- University of Alberta Hospital
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- pre-lung transplant:subjects who are included on the waiting list and are being seen at the out-patient clinic
- post-lung transplant subjects.
Exclusion Criteria:
- younger than 18 years of age
- diagnosed as being cognitively impaired
- unable to complete questionnaires in English
Studijní plán
Jak je studie koncipována?
Kohorty a intervence
Skupina / kohorta |
Intervence / Léčba |
|---|---|
|
Řízení
|
Patients completed the HUI2 and HUI3 before the encounter with the clinician, the result was graphically represented in the HUI score card.
Clinicians used the HUI score card as an extra tool to help them in the management of the patients
Ostatní jména:
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Communication Score
Časové okno: Baseline and end of study (6 months)
|
Each clinician-patient encounter was audio tape-recorded.
The content of the tape-recordings was examined and results recorded on the communication form by three blinded raters.
This form tallies the number of issues discussed.
The number of issues is summed to produce a communication score.
The issues discussed included health attributes included in the HUI2 and HUI3: ambulation, self-care, anxiety, depression, cognitive problems, pain (type and frequency), vision, hearing speech and dexterity problems.
|
Baseline and end of study (6 months)
|
|
Management Composite
Časové okno: At baseline and end of study (6 months)
|
Changes in clinical management were recorded in the chart review form.
The number of referrals to other healthcare providers, tests ordered (X-rays, blood test, bronchoscopies) and changes in medication (reduction or increase dosage, addition or discontinuation) were summed to produce the management composite.
|
At baseline and end of study (6 months)
|
|
EuroQol, EQ-5D.
Časové okno: At baseline and end of study (6 months).
|
Generic preference-based measure.
EQ-5D consists of two sections: a 100-point visual analog scale (VAS) and a descriptive system that contains five attributes (mobility, self-care, usual activities, pain or discomfort, and anxiety or depression) with three levels per attribute ("no problem", "some problems" and "extreme problems").Using the US scoring function EQ-5D index scores range from -0.11 (all-worst health state, worse than dead), to 0.00 (dead) to 1.00 (perfect health).
The EQ-5D is easy to complete, valid and reliable.
|
At baseline and end of study (6 months).
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
The Hospital Anxiety and Depression Scale,HADS. Completed at Baseline and End of the Study.
Časové okno: Baseline and end of study (6 months)
|
HADS is a self-complete mental health measure.
The scale consists of 14 items, seven of which assess anxiety and seven which assess depression.
Each item is on a four point scale and the scores are added to give a total ranging from 0 to 21 for anxiety and 0 to 21 for depression.
Higher scores indicate more severe anxiety or depression.
A cut-point of 8 or 9 indicates mild burden for the two scales; 11 or 12 indicates severe .
All the patients completed HADS at baseline and at the end of the study.
|
Baseline and end of study (6 months)
|
Spolupracovníci a vyšetřovatelé
Sponzor
Vyšetřovatelé
- Vrchní vyšetřovatel: David H Feeny, PhD, Professor Economics, University of Alberta
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhad)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
- Nemoci trávicího systému
- Patologické procesy
- Kardiovaskulární choroby
- Cévní onemocnění
- Nemoci dýchacích cest
- Plicní onemocnění
- Kojenec, novorozenec, nemoci
- Genetické choroby, vrozené
- Onemocnění slinivky břišní
- Hypertenze
- Fibróza
- Plicní onemocnění, obstrukční
- Plicní onemocnění, chronická obstrukční
- Plicní fibróza
- Cystická fibróza
- Hypertenze, plicní
Další identifikační čísla studie
- IHE-188
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .